Literature DB >> 12477431

Viral evolution and challenges in the development of HIV vaccines.

Dan H Barouch1, Norman L Letvin.   

Abstract

Potent virus-specific cytotoxic T lymphocyte (CTL) responses elicited by candidate AIDS vaccines have been shown to provide short-term control of viral replication following pathogenic viral challenges in rhesus monkeys. We have recently shown that vaccines that control rather than prevent immunodeficiency virus infections are still subject to immune escape. In particular, viral mutations can develop that result in viral escape from recognition by immunodominant CTL, loss of immune control of viral replication, and clinical disease progression. These data suggest that viral escape from CTL may prove to be a significant limitation of the current generation of CTL-based AIDS vaccines.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12477431     DOI: 10.1016/s0264-410x(02)00390-0

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

1.  Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies.

Authors:  Bo Peng; Liqun Rejean Wang; Victor Raúl Gómez-Román; Alberta Davis-Warren; David C Montefiori; V S Kalyanaraman; David Venzon; Jun Zhao; Elaine Kan; Thomas J Rowell; Krishna K Murthy; Indresh Srivastava; Susan W Barnett; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

2.  Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome.

Authors:  James P McGettigan; Kristin Naper; Jan Orenstein; Martin Koser; Philip M McKenna; Matthias J Schnell
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

3.  Selective induction of cell-mediated immunity and protection of rhesus macaques from chronic SHIV(KU2) infection by prophylactic vaccination with a conserved HIV-1 envelope peptide-cocktail.

Authors:  Pramod N Nehete; Bharti P Nehete; Lori Hill; Pallavi R Manuri; Veerabhadran Baladandayuthapani; Lei Feng; Johnny Simmons; K Jagannadha Sastry
Journal:  Virology       Date:  2007-10-24       Impact factor: 3.616

4.  Contribution of CD8+ T cells to containment of viral replication and emergence of mutations in Mamu-A*01-restricted epitopes in Simian immunodeficiency virus-infected rhesus monkeys.

Authors:  Eun-Young Kim; Ronald S Veazey; Roland Zahn; Kimberly J McEvers; Susanne H C Baumeister; Gabriel J Foster; Melisa D Rett; Michael H Newberg; Marcelo J Kuroda; E Peter Rieber; Michael Piatak; Jeffrey D Lifson; Norman L Letvin; Steven M Wolinsky; Jörn E Schmitz
Journal:  J Virol       Date:  2008-03-26       Impact factor: 5.103

5.  Covalently linked human immunodeficiency virus type 1 gp120/gp41 is stably anchored in rhabdovirus particles and exposes critical neutralizing epitopes.

Authors:  Philip M McKenna; Roger J Pomerantz; Bernhard Dietzschold; James P McGettigan; Matthias J Schnell
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

Review 6.  Emerging complexities of APOBEC3G action on immunity and viral fitness during HIV infection and treatment.

Authors:  Mahdis Monajemi; Claire F Woodworth; Jessica Benkaroun; Michael Grant; Mani Larijani
Journal:  Retrovirology       Date:  2012-04-30       Impact factor: 4.602

Review 7.  Cytokine-adjuvanted HIV-DNA vaccination strategies.

Authors:  Franco Lori; David B Weiner; Sandra A Calarota; Laurene M Kelly; Julianna Lisziewicz
Journal:  Springer Semin Immunopathol       Date:  2006-10-20

8.  Transmission of HIV-1 CTL escape variants provides HLA-mismatched recipients with a survival advantage.

Authors:  Denis R Chopera; Zenda Woodman; Koleka Mlisana; Mandla Mlotshwa; Darren P Martin; Cathal Seoighe; Florette Treurnicht; Debra Assis de Rosa; Winston Hide; Salim Abdool Karim; Clive M Gray; Carolyn Williamson
Journal:  PLoS Pathog       Date:  2008-03-21       Impact factor: 6.823

9.  Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response.

Authors:  Nicola A Jones; Xiping Wei; Darren R Flower; Mailee Wong; Franziska Michor; Michael S Saag; Beatrice H Hahn; Martin A Nowak; George M Shaw; Persephone Borrow
Journal:  J Exp Med       Date:  2004-11-15       Impact factor: 14.307

10.  HIV CTL escape: at what cost?

Authors:  Stephen M Smith
Journal:  Retrovirology       Date:  2004-05-12       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.